CS1-PEPTIDE

European patent · EP3384919 · In force

Register entry

Publication number
EP3384919
Application number
EP18162674
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Jun 1, 2009
Published
Oct 10, 2018
Granted
Apr 1, 2026
Protection ends at the latest
May 31, 2029
Next annual fee due
Jun 30, 2026
IPC classes
A61K 38/00 (2006.01)
C07K 14/705 (2006.01)
C07K 14/47 (2006.01)
A61P 35/02 (2006.01)
A61P 43/00 (2006.01)
A61K 40/11 (2025.01)
A61K 40/42 (2025.01)
A61P 35/00 (2006.01)
A61P 39/00 (2006.01)
Priority
US 58180 P 02.06.2008
Divided from
EP09759182
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Apr 17, 2026

    Agent entered

    Representative
    MICHELI & CIE SA, 122, rue de Genève,, CP 61, 1226 Thônex

    Published in Swissreg on 17.04.2026

  2. Apr 1, 2026

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 01.04.2026

Parties

Holder

Dana-Farber Cancer Institute, Inc.

450 Brookline Avenue, Boston, MA 02215, US

Agent

MICHELI & CIE SA

122, rue de Genève, CP 61, 1226 Thônex

Inventor

BAE, Jooeun

West Roxbury, MA 02132, US

ANDERSON, Kenneth

Wellesley, MA 02482, US

MUNSHI, Nikhil

Needham, MA 02494, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.